topical rose oil in the patients with migraine headache

Efficacy and side effects of topical rose oil in the treatment of acute migraine headache

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201511257297N2

Enrollment

Registered

2015-12-12

Start date

2015-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine headache. migraine without aura(common migraine) and migraine with aura(classical migraine)

Interventions

Intervention 1: essential rose oil as a drug, 7cc, almost 2cc in every attack used topical in temporal and frontal area, interval of attacks was minimum 1 week as washout period. Intervention 2: Liqu

Treatment - Drugs

essential rose oil as a drug, 7cc, almost 2cc in every attack used topical in temporal and frontal area, interval of attacks was minimum 1 week as washout period

Liquid paraffin as a placebo, 7cc, almost 2cc in every attack used topical in temporal and frontal area, interval of attacks was minimum 1 week as washout period

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:patients with migraine headache based on 3th edition of IHS and ICHD criteria, age over 18 years, having at least 2 migraine headache every months. exclusion criteria:sensitivity to rose flowersl, pregnancy, don't sign informative testimonial, getting worse headache intensity with olphactory stimulation of drug or placebo, new diagnosed case with indication of preventive therapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain intensity. Timepoint: 0 min, 15min, 30 min, 45 min, 60 min, 90 min, 120 min, 6 hr, 12 hr, 24hr. Method of measurement: visual analogue scale of pain(VAS).;Photophobia. Timepoint: 0 min, 30 min, 2hr. Method of measurement: visual analogue scale of pain(VAS).;Nausea/vomiting. Timepoint: 0 min, 30 min, 2hr. Method of measurement: visual analogue scale of pain(VAS).;Get away of sound. Timepoint: 0 min, 30 min, 2hr. Method of measurement: visual analogue scale of pain(VAS).	—

Measure

Time frame

Pain intensity. Timepoint: 0 min, 15min, 30 min, 45 min, 60 min, 90 min, 120 min, 6 hr, 12 hr, 24hr. Method of measurement: visual analogue scale of pain(VAS).;Photophobia. Timepoint: 0 min, 30 min, 2hr. Method of measurement: visual analogue scale of pain(VAS).;Nausea/vomiting. Timepoint: 0 min, 30 min, 2hr. Method of measurement: visual analogue scale of pain(VAS).;Get away of sound. Timepoint: 0 min, 30 min, 2hr. Method of measurement: visual analogue scale of pain(VAS).

—

Secondary

Measure	Time frame
Any adverse reaction to the intervention. Timepoint: 0min, 15min, 30min,45min, 60min, 90min, 120min, 6hr, 12hr, 24hr. Method of measurement: visual analogue scale of pain(VAS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaria Niazi

shiraz university of medical science

maria_niazi98@yahoo.com+98 71 3230 5886

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026